ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄ΠΎΠ±Π°Π²Π»Π΅Π½Π½ΡΠ΅ Π²ΠΈΠ΄Π΅ΠΎ:
pembrolizumab-en-cancer-de-esofago
-
5 Π»Π΅Ρ Π½Π°Π·Π°Π΄
1700 5 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 2:23Pembrolizumab plus chemotherapy for esophageal cancer: KEYNOTE-590
-
10 Π»Π΅Ρ Π½Π°Π·Π°Π΄
485 10 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 1:54Pembrolizumab in Advanced Gastric Cancer Treatment
-
6 Π»Π΅Ρ Π½Π°Π·Π°Π΄
172 6 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 1:53David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer
-
3 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
240 3 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 32:47ΠΠ½Π΅ΡΠ΅Π½ΠΈΠ΅ Π½ΠΎΠ²ΡΡ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ° ΠΆΠ΅Π»ΡΠ΄ΠΊΠ°
-
6 Π»Π΅Ρ Π½Π°Π·Π°Π΄
32 6 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 4:50Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
-
7 Π»Π΅Ρ Π½Π°Π·Π°Π΄
1323 7 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 1:54Exploring Immunotherapy in Patients With Esophageal Cancer
-
1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄
257 1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄ 22:13ΠΠΎΠ²ΠΎΠ΅ Π² ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΌΠ΅ΡΡΠ½ΠΎΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
272 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 8:45KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
-
1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄
392 1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄ 1:28:01ΠΠΌΠΌΡΠ½ΠΎΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡ. ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² (Π²Π΅Π±ΠΈΠ½Π°Ρ 18 ΠΎΠΊΡΡΠ±ΡΡ 2023)
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
253 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 15:04ΠΠ΄ΡΡΠ²Π°Π½ΡΠ½Π°Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ: ΡΠΎΠ»ΡΠΊΠΎ ΠΏΡΠΈ ΠΌΠ΅Π»Π°Π½ΠΎΠΌΠ΅?
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
360 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 1:56Eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
2561 4 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 30:31Gastroesophageal Cancer: Current Positioning of Immunotherapy
-
6 Π»Π΅Ρ Π½Π°Π·Π°Π΄
9181 6 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 46:42Cancer Patient Perspectives Panel at 2019 CRI Immunotherapy Patient Summit in NYC
-
2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
43 2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 15:48ESOPHAGEAL CANCER AND PEMBROLIZUMAB
-
1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄
235 1 Π³ΠΎΠ΄ Π½Π°Π·Π°Π΄ 1:10KEYNOTE-811: HRQOL pembro plus tras and chemo in first-line HER2+ advanced gastric cancer
-
7 Π»Π΅Ρ Π½Π°Π·Π°Π΄
386 7 Π»Π΅Ρ Π½Π°Π·Π°Π΄ 6:50PD-1 Inhibitors for Advanced Gastroesophageal Cancer
-
2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄
236 2 Π³ΠΎΠ΄Π° Π½Π°Π·Π°Π΄ 1:07KEYMAKER-U06 substudy 06A: favezelimab or MK-4380 in esophageal cancer